Esperas Pharma Inc. will begin clinical development of a new anti-cancer product at major Montreal hospitals

- Health
  0

Left to right: Gaétan Morin, President and CEO, Fonds de solidarité FTQ; Luc Marengere, Managing Partner, TVM Capital; L'’honorable Denis Coderre, maire de Montréal; Caroline Fortier, CEO, Esperas Pharma Inc.; Dr. Gerald Batist, Scientific Director, Q-CROC; Vincent Poitout, Scientific Director, CRCHUM (CNW Group/Esperas Pharma inc.)In partnership with the Q-CROC, Esperas will invest up to $7M in a clinical trial that aims to provide first access to promising new treatment for Quebec cancer patients

Link to Backgrounder about clinical trial

MONTREAL, April 11, 2016 /CNW Telbec/ – Esperas Pharma Inc. (“Esperas”)…